Creating engaging, compliant risk-management plans
Our client asked Ashfield MedComms to produce risk-management plan manuals targeted at different stakeholder groups. The plans were part of the commercialisation of a new chimeric antigen receptor T-cell (CAR-T) therapy for treating multiple myeloma.
The team began by scheduling a series of advisory board meetings with each stakeholder group to identify specific content. Stakeholders included CAR-T physicians, referral physicians, pharmacists, nurses and patients.
That complex information was then shaped and presented in a creative and engaging way, including clear messaging, graphics and icons to ensure accessibility, compliance and maximum impact. In particular, the Ashfield MedComms patient engagement team ensured the patient guide had the right level of messaging for the target audience.
The materials were then reviewed by our Advanced Therapy Medicine Produce Council to ensure they were fit for European Medicines Agency and approval.
The manuals were a success and now another is being developed specifically for caregivers. The client has also asked Ashfield MedComms to adapt the information for interactive online platforms for HCPs and patients.
Discover more about EmerGENE
EmerGENE is the first multidisciplinary, global network of experts from across Ashfield and Sharp all passionately focused on the success of your cell and gene therapy.